Monitoring cytomegalovirus infection in ovarian cancer patients using saliva
Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment
This study tests if using saliva samples can help track cytomegalovirus infection in women with ovarian cancer who are undergoing treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 28 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 2 sites (Minneapolis, Minnesota and 1 other locations) |
| Trial ID | NCT06870539 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility and accuracy of using saliva samples to remotely monitor cytomegalovirus (CMV) infection in patients undergoing treatment for ovarian cancer. It aims to determine how effectively saliva can be used as a non-invasive method for tracking CMV infection and related symptoms during cancer treatment. The study includes patients diagnosed with ovarian cancer who are actively receiving treatment, regardless of their disease status. Participants will be monitored for CMV infection through saliva analysis, providing insights into the relationship between CMV and cancer treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with ovarian cancer and are currently receiving treatment.
Not a fit: Patients who are pregnant, unable to provide informed consent, or have a history of cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved monitoring and management of CMV infections in ovarian cancer patients, potentially enhancing treatment outcomes.
How similar studies have performed: While the use of saliva for monitoring infections is a growing field, this specific approach to CMV in ovarian cancer patients is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 * Ability to read and write in English * Diagnosed with ovarian cancer (ovarian, primary peritoneal, fallopian tube) * Receiving care from providers at Mayo Clinic * Regardless of diseases status, actively receiving treatment for ovarian cancer (frontline, maintenance, progression, recurrence) Exclusion Criteria: * Pregnant at the time of study participation * Inability to provide informed written consent * History of dementia, stroke, brain tumors or other condition which may impair cognitive functioning
Where this trial is running
Minneapolis, Minnesota and 1 other locations
- University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota, United States (Recruiting)
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Amanika Kumar, MD — Mayo Clinic in Rochester
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.